eMedicine Specialties > Otolaryngology and Facial Plastic Surgery > Cosmetic Surgery

Skin Resurfacing: Laser Surgery

Author: Neil Tanna, MD, Staff Physician, Division of Otolaryngology-Head and Neck Surgery, George Washington University Medical Center
Coauthor(s): Steven B Hopping, MD, FACS, Clinical Professor of Surgery, George Washington University Hospital; Director, Center for Cosmetic Surgery
Contributor Information and Disclosures

Updated: Mar 21, 2008

Introduction

Ablative facial resurfacing involves wounding the skin to the dermal level, thereby removing photodamaged areas of the epidermis. Dermal wound healing stimulates collagen production. Ultimately, ultrastructural remodeling results in rejuvenated skin. Resurfacing occurs at the following 3 levels:

  • Superficial (wounds from the stratum corneum through the papillary dermis)
  • Medium (wounds of the upper reticular dermis)
  • Deep (wounds of the midreticular dermis)

Options for ablative facial resurfacing include chemical peeling, dermabrasion, and laser surgery.

The popularity of dermabrasion has diminished because of an increased prevalence and awareness of blood-borne pathogens. Additionally, maintaining the proper depth during dermabrasion is technically difficult. Dermabrasion can be used for the treatment of facial rhytides; however, it is better suited for the treatment of facial scars.

While superficial peeling agents (eg, glycolic acid) remain popular, they do not penetrate the dermis. A medium-to-deep chemical peel must be used to perform ablative resurfacing. However, the use of medium and deep peeling agents has diminished. This trend probably reflects the greater operator control that lasers provide.

Laser skin resurfacing (LSR) has become an important component of rejuvenation surgery. The results in treating severely photodamaged skin, photoinduced facial rhytides, dyschromias, and atrophic scars have been favorable. In addition, LSR has been used for benign epidermal and dermal lesions and certain premalignant and malignant skin lesions. Finally, LSR can be performed as an isolated procedure or as an adjunct to procedures such as transconjunctival blepharoplasty (TCB), facelift, and endoscopic browlift.

Although this technology is relatively new, its benefits are clear. The laser allows for precise control of ablation depth, and it permits the surgeon to vary these depths as needed. In addition to such precision, LSR causes favorable heating of the dermis, which tightens collagen fibers and stimulates neocollagen secretion by fibroblasts.

Currently, 2 laser wavelengths are in common use for facial skin resurfacing: pulsed carbon dioxide (CO2) and erbium:yttrium-aluminum-garnet (Er:YAG). The practice of combining these wavelengths in sequence is also gaining popularity. The latest generation of resurfacing lasers combines Er:YAG with subablative carbon dioxide energy in the same unit. The operative principles of these lasers and their use are described in this article. Although specific models with which the author has experience are discussed, the same principles apply to those from other manufacturers.

Comparison of tissue effects of carbon dioxide and Er:YAG lasers

Each Er:YAG pulse removes only 25-30 µm of tissue compared to the pulsed carbon dioxide, which removes 50-100 µm.

The laser output of Er:YAG is directly absorbed by collagen and dermal proteins, whereas the carbon dioxide laser vaporizes extracellular water in the dermis. Each Er:YAG pass generates the same amount of ablation, whereas the pulsed carbon dioxide generates a decreased vaporization depth with each pass. Also, a very small additive effect of increasing thermal damage occurs with the number of passes; proportionately, pulsed carbon dioxide has more energy contributing to thermal damage per pass.

Carbon dioxide laser

The CO2 laser (wavelength of 10,600 nm) is absorbed by tissue water, causing the temperature of the water to rise to more than 100°C. The laser penetrates approximately 30 µm within the skin. Thermal injury is prevented when the laser pulsewidth is less than the thermal relaxation time of the tissue (the time required for 50% of the heat to diffuse). The critical pulsewidth is less than 1 millisecond.

The first pass of the CO2 laser causes approximately 50-70 µm of ablation. Since the resulting layer of thermal necrosis has less tissue water than the uninjured skin, successive passes result in less tissue vaporization. With each pass, however, the total depth of thermal necrosis increases slightly. Keep in mind that the thermal necrosis does not exceed a depth of 100 µm if the pulsewidth is kept at less than 1 millisecond.

Fluence (energy density) rather than peak power is more clinically relevant to tissue ablation because it is a measure of the energy (in J) delivered to the treatment region (in cm2) based on spot size. Increasing the fluence increases the depth of ablation. The threshold for skin vaporization is approximately 5 J/cm2. A fluence of 5-7 J/cm2 provides clean and efficient tissue ablation and dissipates much of the heat in the plume of vaporized tissue.

Er:YAG laser

The Er:YAG laser (wavelength of 2940 nm) offers precise tissue ablation with minimal thermal damage. This wavelength corresponds to the main peak of water absorption. When compared with the CO2 laser, the Er:YAG laser is more efficiently absorbed by water-containing tissues. Since the epidermis is mostly water, the Er:YAG laser is more superficially absorbed. This translates into less collateral thermal damage.

Pulsewidths of 200-350 microseconds result in thermal necrosis of less than 10 µm in depth. Unlike the CO2 laser, with successive passes of the Er:YAG laser, the thermal injury depth remains stable. Additionally, stacking Er:YAG pulses slightly reduces the ablative efficiency. With the CO2 laser, the ablative efficiency decreases with successive passes.

The vaporization threshold of the Er:YAG laser is between 0.5 and 1.7 J/cm2. The fluence and depth of tissue ablation are directly related. For every J/cm2, 2-4 µm of tissue depth is ablated. This allows for precise control of tissue ablation.

Combined carbon dioxide and Er:YAG laser

The benefit of a combined system is derived from the precise tissue ablation and minimal necrosis of Er:YAG systems coupled with the favorable heating of deeper tissue layers typical of carbon dioxide systems. A distinct advantage of this laser is that the nuisance of oozing with Er:YAG alone is avoided with the addition of coagulative carbon dioxide effects. In addition, fewer passes are required to reach depths equivalent to those of Er:YAG alone.

Carbon dioxide and Er:YAG lasers in sequence

Carbon dioxide laser treatment followed by Er:YAG results in thermal necrosis and collagen injury similar to those of Er:YAG alone. This phenomenon may be secondary to Er:YAG removal of carbon dioxide thermal injury. In other words, following carbon dioxide passes with Er:YAG removes the zone of thermal necrosis and promotes prompt healing.

Indications

In considering laser skin resurfacing (LSR), the clinician should consider the patient's skin type. This sun-reactive skin type (Fitzpatrick) is recorded preoperatively.

Fitzpatrick sun-reactive skin types and skin color tanning response

  • Type I - White, always burns, never tans
  • Type II - White, usually burns, tans with difficulty
  • Type III - White, sometimes burns mildly, achieves average tan
  • Type IV - Brown, rarely burns, tans with ease
  • Type V - Dark brown, very rarely burns, tans very easily
  • Type VI - Black, never burns, tans very easily

Patients with Fitzpatrick type I or II skin are generally better candidates for LSR. Nonablative techniques usually offer better results to individuals with type III skin and greater. These patients are often at risk for postprocedure pigmentary changes.

The carbon dioxide laser is well suited to the treatment of perioral vertical furrows, periorbital dynamic lines (crow's feet) and mild dermatochalasis, glabellar dynamic lines, actinic damage, generalized facial elastosis, shallow scars, and epidermal-dermal lesions. When treating crow's feet dynamic lines, ensure that the patient understands that the benefit is apparent only when in repose (ie, the furrows reappear upon squinting [unless botulinum toxin type A is also used]).

The Er:YAG laser causes more superficial tissue ablation compared with the CO2 laser. Therefore, patients with actinic damage, dyschromias, mild photodamaged skin, or superficial rhytides are excellent candidates for Er:YAG skin resurfacing. An equally important factor is patient request for early recovery (ie, patients may want laser treatment but request that they not appear red for months). Unlike the carbon dioxide laser, Er:YAG appears safe for use on the skin of the neck, chest, and hands, which expands its role. Additionally, a decreased incidence of hyperpigmentation with skin types IV and V may be associated with use of the Er:YAG.

The patient's wrinkle severity is classified preoperatively. Regions are graded on a scale of 1-6 (1 means essentially unwrinkled; 6 is profoundly wrinkled). Repeat treatments may yield the most optimal results. Treatment for patients with severe rhytides should be planned in this manner. Retreatments are generally spaced 4 months apart.

Contraindications

Absolute contraindications include active acne, deep acne pits or picks, and isotretinoin (Accutane) use in the past 2 years. Accutane is effective for cystic acne because it targets the sebaceous glands. However, a compromise in gland function impairs skin reepithelialization and increases the risk of scarring. Similarly, patients with reduced adnexal structures (eg, scleroderma, irradiation or burns) are poor candidates. History of herpetic infection is a relative contraindication only because most patients do not know their true status. Smokers are not excluded, which is a clear advantage over standard rhytidectomy.

More on Skin Resurfacing: Laser Surgery

Overview: Skin Resurfacing: Laser Surgery
Treatment: Skin Resurfacing: Laser Surgery
Follow-up: Skin Resurfacing: Laser Surgery
References

References

  1. West TB, Alster TS. Effect of pretreatment on the incidence of hyperpigmentation following cutaneous CO2 laser resurfacing. Dermatol Surg. Jan 1999;25(1):15-7. [Medline].

  2. Alster TS. Cutaneous resurfacing with CO2 and erbium: YAG lasers: preoperative, intraoperative, and postoperative considerations. Plast Reconstr Surg. Feb 1999;103(2):619-32; discussion 633-4. [Medline].

  3. Alster TS. Side effects and complications of laser surgery. In Alster TS: Manual of Cutaneous Laser Techniques, ed 2. Philadelphia, Lippinco. 2000;pp 175-187.

  4. Alster TS, Lupton JR. Treatment of complications of laser skin resurfacing. Arch Facial Plast Surg. Oct-Dec 2000;2(4):279-84. [Medline].

  5. Newman JP, Koch RJ, Goode RL. Closed dressings after laser skin resurfacing. Arch Otolaryngol Head Neck Surg. Jul 1998;124(7):751-7. [Medline].

  6. Nowak KC, McCormack M, Koch RJ. The effect of superpulsed carbon dioxide laser energy on keloid and normal dermal fibroblast secretion of growth factors: a serum-free study. Plast Reconstr Surg. May 2000;105(6):2039-48. [Medline].

  7. Utley DS, Koch RJ, Egbert BM. Histologic analysis of the thermal effect on epidermal and dermal structures following treatment with the superpulsed CO2 laser and the erbium: YAG laser: an in vivo study. Lasers Surg Med. 1999;24(2):93-102. [Medline].

  8. Walsh JT Jr, Flotte TJ, Anderson RR. Pulsed CO2 laser tissue ablation: effect of tissue type and pulse duration on thermal damage. Lasers Surg Med. 1988;8(2):108-18. [Medline].

Further Reading

Keywords

laser skin resurfacing, LSR, laser abrasion, laser skin rejuvenation, cosmetic skin resurfacing, laser surgery, skin resurfacing, photodamaged skin, rejuvenated skin, collagen production, laser surgery, Er:YAG, Er:YAG laser

Contributor Information and Disclosures

Author

Neil Tanna, MD, Staff Physician, Division of Otolaryngology-Head and Neck Surgery, George Washington University Medical Center
Neil Tanna, MD is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, American Medical Association, and Medical Society of the District of Columbia
Disclosure: Nothing to disclose.

Coauthor(s)

Steven B Hopping, MD, FACS, Clinical Professor of Surgery, George Washington University Hospital; Director, Center for Cosmetic Surgery
Steven B Hopping, MD, FACS is a member of the following medical societies: American Academy of Cosmetic Surgery, American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, American Medical Association, American Society of Lipo-Suction Surgery, and Medical Society of the District of Columbia
Disclosure: Nothing to disclose.

Medical Editor

J David Kriet, MD, FACS, Associate Professor, Department of Otolaryngology-Head and Neck Surgery, Director of Facial Plastic and Reconstructive Surgery, University of Kansas School of Medicine
J David Kriet, MD, FACS is a member of the following medical societies: Alpha Omega Alpha, American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, American Cleft Palate/Craniofacial Association, American College of Surgeons, American Medical Association, AO Foundation, and Society of University Otolaryngologists-Head and Neck Surgeons
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Keith A LaFerriere, MD, Clinical Professor, Fellowship Director, Department of Surgery, Division of Otolaryngology, University of Missouri at Columbia
Keith A LaFerriere, MD is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, American Medical Association, and Missouri State Medical Association
Disclosure: Nothing to disclose.

CME Editor

Christopher L Slack, MD, Otolaryngology-Facial Plastic Surgery, Private Practice, Associated Coastal ENT; Medical Director, Treasure Coast Sleep Disorders
Christopher L Slack, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, and American Medical Association
Disclosure: Nothing to disclose.

Chief Editor

Arlen D Meyers, MD, MBA, Professor, Department of Otolaryngology-Head and Neck Surgery, University of Colorado School of Medicine
Arlen D Meyers, MD, MBA is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, and American Head and Neck Society
Disclosure: Advanced Headache Intervention Consulting fee Consulting; Covidien Corp Consulting fee Consulting

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.